Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
BioCryst Pharmaceuticals revenue
BioCryst Pharmaceuticals's revenue is $450.7 million.
What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals's revenue growth from 1999 to 2024 is 8,358.16%.
- BioCryst Pharmaceuticals has 110 employees, and the revenue per employee ratio is $4,097,381.
- BioCryst Pharmaceuticals's peak quarterly revenue was $131.5M in 2024(q4).
- BioCryst Pharmaceuticals peak revenue was $450.7M in 2024.
- BioCryst Pharmaceuticals annual revenue for 2023 was 331.4M, 22.37% growth from 2022.
- BioCryst Pharmaceuticals annual revenue for 2024 was 450.7M, 36.0% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
BioCryst Pharmaceuticals historical revenue
BioCryst Pharmaceuticals's peak revenue was $450.7M in 2024. The peak quarterly revenue was $131.5M in 2024(q4).
BioCryst Pharmaceuticals's revenue increased from $5.3m in 1999 to $450.7M currently. That's a 8,358.16% change in annual revenue.
BioCryst Pharmaceuticals annual revenue
BioCryst Pharmaceuticals annual revenue over time
| Fiscal year / year | BioCryst Pharmaceuticals revenue |
|---|---|
| 2009 | $5.4M |
| 2010 | $62.4M |
| 2011 | $19.6M |
| 2012 | $26.3M |
| 2013 | $17.3M |
| 2014 | $13.6M |
| 2015 | $48.3M |
| 2016 | $26.4M |
| 2017 | $25.2M |
| 2018 | $20.7M |
| 2019 | $48.8M |
| 2020 | $17.8M |
| 2021 | $157.2M |
| 2022 | $270.8M |
| 2023 | $331.4M |
| 2024 | $450.7M |
Rate BioCryst Pharmaceuticals' financial transparency
BioCryst Pharmaceuticals annual growth
BioCryst Pharmaceuticals saw the greatest revenue growth in 2010, when revenue increased by 1,047.76%.
BioCryst Pharmaceuticals had the lowest revenue growth in 2009, when revenue changed by -90.39%.
BioCryst Pharmaceuticals annual growth rate over time
| Year | BioCryst Pharmaceuticals growth |
|---|---|
| 2009 | -90%↓ |
| 2010 | 1048%↑ |
| 2011 | -69%↓ |
| 2012 | 34%↑ |
| 2013 | -34%↓ |
| 2014 | -21%↓ |
| 2015 | 255%↑ |
| 2016 | -45%↓ |
| 2017 | -4%↓ |
| 2018 | -18%↓ |
| 2019 | 136%↑ |
| 2020 | -64%↓ |
| 2021 | 782%↑ |
| 2022 | 72%↑ |
| 2023 | 22%↑ |
| 2024 | 36%↑ |
BioCryst Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
BioCryst Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | - | - | - | $39.7M |
| 2020 | $4.8M | $2.9M | $6.1M | $4.0M |
| 2021 | $19.1M | $50.0M | $41.0M | $47.2M |
| 2022 | $49.9M | $65.5M | $75.8M | $79.5M |
| 2023 | $68.8M | $82.5M | $86.7M | $93.4M |
| 2024 | $92.8M | $109.3M | $117.1M | $131.5M |
BioCryst Pharmaceuticals jobs nearby
Do you work at BioCryst Pharmaceuticals?
Is BioCryst Pharmaceuticals transparent about its revenue structure?
BioCryst Pharmaceuticals financial information
| CEO | Jon P. Stonehouse |
| Industry | Health Care Equipment & Services |
| Company Type | Public |
| Employees Number | 110 |
| Date Founded | 1986 |
| Headquarters | Durham, North Carolina |
| Number of Locations | 2 |
| Revenue | $450.7M |
| Net Income | -$247,116,000 |
| Gross Proft | $438.4M (2024) |
| PE Ratio | -10.62 |
| Tax Rate | -0.0% |
| Market Capitalization | $944.0M |
| Total Assets | $550,000,000 |
| Ticker | BCRX |
BioCryst Pharmaceuticals jobs you might like
BioCryst Pharmaceuticals financing
BioCryst Pharmaceuticals received early financing of $5.0M on 2013-09-12.
| Series | Round size | Date |
|---|---|---|
| Grant | $5M | 09/2013 |
| Grant | $2.5M | 12/2013 |
| Post Ipo Equity | $1.9M | 06/2014 |
| Post Ipo Equity | $4M | 08/2014 |
| Grant | $2.4M | 08/2014 |
| Post Ipo Debt | $23M | 09/2016 |
| Post Ipo Equity | $92M | 09/2017 |
| Post Ipo Equity | $57.5M | 08/2018 |
| Grant | $34.7M | 09/2018 |
| Post Ipo Equity | $3.5M | 09/2018 |
| Post Ipo Debt | $100M | 02/2019 |
| Post Ipo Equity | $63M | 11/2019 |
| Post Ipo Equity | $82M | 05/2020 |
| Post Ipo Equity | $115M | 06/2020 |
| Grant | $44M | 08/2020 |
| Post Ipo Debt | $325M | 12/2020 |
| Post Ipo Equity | $350M | 11/2021 |
BioCryst Pharmaceuticals investors
| Investors | Security type |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Grant |
| National Institutes of Health (NIH) | Post Ipo Equity |
| MidCap Financial | Post Ipo Debt |
| CDC | Grant |
| MidCap Financial | Post Ipo Debt |
| Athyrium Capital Management LP | Post Ipo Debt |
| ROYALTY PHARMA PLC | Post Ipo Debt |
| ROYALTY PHARMA PLC | Post Ipo Equity |
| Omers | Post Ipo Equity |
BioCryst Pharmaceuticals competitors
BioCryst Pharmaceuticals's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
BioCryst Pharmaceuticals's smallest competitor is Chimerix with revenue of $212.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Chimerix | - | $212,000 | 82 | - |
| Intezyne Technologies | - | $2.8M | 8 | - |
| Signum Biosciences | - | $1.5M | 13 | - |
| Gilead Sciences | - | $28.8B | 11,800 | - |
| Sarepta Therapeutics | - | $1.9B | 840 | - |
| TriLink BioTech | - | $17.5M | 50 | - |
| Eurofins DiscoverX | - | $8.5M | 150 | - |
| Alios BioPharma | - | $15.7M | 75 | - |
BioCryst Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
BioCryst Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of BioCryst Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about BioCryst Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at BioCryst Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by BioCryst Pharmaceuticals. The data presented on this page does not represent the view of BioCryst Pharmaceuticals and its employees or that of Zippia.
BioCryst Pharmaceuticals may also be known as or be related to BIOCRYST PHARMACEUTICALS INC, BioCryst Pharmaceuticals, BioCryst Pharmaceuticals Inc, BioCryst Pharmaceuticals, Inc. and Biocryst Pharmaceuticals, Inc.